Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
India · Delayed Price · Currency is INR 2,437.20
-21.80 (-0.89%)
Sep 4, 2026, 3:14 PM IST
Glenmark Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 687,780 | 601,567 | 434,866 | 270,463 | 131,124 | 124,718 | |
Market Cap Growth | 27.02% | 38.33% | 60.79% | 106.27% | 5.14% | -4.88% |
Enterprise Value | 681,949 | 586,905 | 434,470 | 315,126 | 164,781 | 152,778 |
Last Close Price | 2437.20 | 2129.58 | 1535.75 | 953.79 | 461.09 | 435.75 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 38.27 | 44.17 | 41.53 | - | 44.11 | 13.24 |
Forward PE | 28.87 | 26.04 | 26.02 | 26.45 | 10.10 | 10.59 |
PS Ratio | 3.88 | 3.53 | 3.25 | 2.14 | 1.13 | 1.01 |
PB Ratio | 6.54 | 5.72 | 4.91 | 3.45 | 1.33 | 1.32 |
P/TBV Ratio | 8.59 | 7.51 | 5.89 | 4.15 | 1.86 | 1.83 |
P/FCF Ratio | 32.95 | 28.82 | - | - | 743.80 | 39.15 |
P/OCF Ratio | 19.96 | 17.46 | - | - | 20.97 | 11.25 |
PEG Ratio | 1.37 | 1.11 | 1.25 | 1.12 | 0.63 | 1.71 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 3.84 | 3.44 | 3.25 | 2.49 | 1.41 | 1.24 |
EV/EBITDA Ratio | 14.11 | 13.10 | 19.19 | 17.22 | 11.53 | 7.99 |
EV/EBIT Ratio | 16.31 | 14.46 | 22.78 | 21.80 | 14.48 | 8.30 |
EV/FCF Ratio | 32.67 | 28.12 | - | - | 934.71 | 47.96 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.28 | 0.16 | 0.47 | 0.42 |
Debt / EBITDA Ratio | 0.12 | 0.13 | 1.05 | 0.64 | 3.03 | 1.98 |
Debt / FCF Ratio | - | 0.28 | - | - | 261.38 | 12.44 |
Net Debt / Equity Ratio | -0.05 | -0.06 | 0.09 | -0.05 | 0.35 | 0.27 |
Net Debt / EBITDA Ratio | -0.12 | -0.13 | 0.35 | -0.24 | 2.41 | 1.33 |
Net Debt / FCF Ratio | - | -0.28 | -0.50 | 0.37 | 195.11 | 7.99 |
Asset Turnover | - | 0.95 | 0.88 | 0.75 | 0.64 | 0.75 |
Inventory Turnover | - | 1.53 | 1.63 | 1.87 | 1.81 | 1.90 |
Quick Ratio | - | 1.11 | 0.94 | 0.75 | 1.06 | 1.08 |
Current Ratio | - | 1.77 | 1.56 | 1.28 | 2.10 | 1.77 |
Return on Equity (ROE) | - | 14.07% | 12.54% | -20.70% | -0.93% | 12.04% |
Return on Assets (ROA) | - | 14.11% | 7.84% | 5.36% | 3.90% | 7.04% |
Return on Invested Capital (ROIC) | 29.90% | 28.48% | 16.74% | -700.97% | -3.36% | 11.09% |
Return on Capital Employed (ROCE) | - | 30.00% | 18.90% | 16.90% | 8.00% | 14.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.61% | 2.26% | 2.41% | -5.55% | 2.27% | 7.55% |
FCF Yield | 3.03% | 3.47% | -3.63% | -4.30% | 0.13% | 2.55% |
Dividend Yield | 0.20% | 0.24% | 0.16% | 0.26% | 0.54% | 0.57% |
Payout Ratio | - | 10.36% | 6.73% | - | 23.68% | 9.84% |
Buyback Yield / Dilution | 0.00% | -0.03% | -0.01% | -0.00% | - | - |
Total Shareholder Return | 0.21% | 0.21% | 0.15% | 0.26% | 0.54% | 0.57% |